Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal amphotericin B + isavuconazole
- Development stage
- Unknown
- Lead developer
- Bin Cao
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Liposomal amphotericin B + isavuconazole is a combination antifungal regimen currently being evaluated in a Phase 4 clinical trial for the treatment of pulmonary mucormycosis. The regimen combines two potent antifungal agents with distinct mechanisms of action: liposomal amphotericin B (AmBisome), a polyene that binds to ergosterol in the fungal cell membrane to create lethal pores, and isavuconazole (Cresemba), a triazole that inhibits the enzyme lanosterol 14-alpha-demethylase (CYP51), thereby blocking the synthesis of ergosterol. This combination is hypothesized to provide synergistic or additive effects against Mucorales species, which are the causative agents of mucormycosis and are associated with high mortality rates in immunocompromised individuals. The trial, led by investigator Bin Cao, aims to establish whether this combination therapy offers improved efficacy and safety compared to liposomal amphotericin B monotherapy.
- Brand names
- AmBisome + Cresemba
- Other names
- AmBisome + isavuconazoleLiposomal Amphotericin B + Isavuconazole
02
Targets
ErgosterolCYP51A1 (Sterol 14α-demethylase)
Beyond the preview
Go deeper on liposomal amphotericin B + isavuconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal amphotericin B + isavuconazole.